钆塞酸增强MRI肝胆期功能参数能否预测肝硬化患者的临床结局?
该队列纳入63例接受钆塞酸MRI并有2年临床随访的肝硬化患者,计算增强率(ER)、对比增强指数(CEI)和对比增强脾指数(CES),评估其与Child-Pugh评分(CPS)、MELD评分预测2年内静脉曲张出血(VB)、肝性脑病(HE)和死亡的价值。结果显示ER 15和CES 20是最佳MRI预测指标,预测VB的AUC分别为0.785和0.729,ER 15<48预测2年内HE的敏感度96%、特异度84%。结论认为ER 15或CES 20对主要并发症和死亡的预测能力等同或优于常用临床评分。
要点
- ER 15和CES 20是预测肝硬化2年内不良结局的最佳MRI功能参数。
- 预测静脉曲张出血的AUC:ER 15为0.785、CES 20为0.729、CPS为0.673、MELD为0.714。
- ER 15<48预测2年内肝性脑病的敏感度96%、特异度84%。
核心结论
- 在肝硬化患者中,ER 15或CES 20对主要并发症和死亡的预测能力等同或优于常用临床评分(CPS、MELD)。
研究设计与样本
- 队列研究,纳入63例接受钆塞酸增强MRI并有2年临床随访的肝硬化患者,计算ER、CEI和CES,并与CPS、MELD评分比较预测价值。
诊断标准与关键数值
- 预测静脉曲张出血的AUC:ER 15为0.785、CES 20为0.729、CPS为0.673、MELD为0.714。
- ER 15<48预测2年内肝性脑病:敏感度96%、特异度84%。
- CES 20与2年内死亡风险相关。
- ER 15与CES 20为最佳MRI预测指标。
临床应用与阅片要点
- ER 15或CES 20对主要并发症和死亡的预测能力等同或优于常用临床评分(CPS、MELD)。
- 钆塞酸参数可能识别有不良事件风险的肝硬化患者。
- 钆塞酸参数通常显示优于临床评分的预测价值。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine the value of quantitative parameters of gadoxetate-enhanced magnetic resonance imaging (MRI) in predicting prognosis in patients with cirrhosis.
METHODS: A cohort of 63 cirrhotic patients who had gadoxetate MRI and 2-year clinical follow-up was enrolled. Enhancement ratio (ER), contrast enhancement index (CEI) and contrast enhancement spleen index (CES) were calculated. The usefulness of these parameters and clinical scores, such as Child-Pugh score (CPS) and model for end stage liver disease (MELD), in predicting adverse outcomes, such as variceal bleeding (VB), hepatic encephalopathy (HE) and mortality at 2 years were evaluated.
RESULTS: Fifteen, 31 and 27 patients, respectively, had VB, HE and mortality within 2 years. The ER at 15 min (ER 15) and CES at 20 min (CES 20) were found to be the best MRI predictors. Areas under the receiver operating characteristic curve (AUC) for predicting VB were 0.785, 0.729, 0.673, 0.714, respectively, for ER 15, CES 20, CPS and MELD scores. ER 15 of less than 48 had sensitivity of 96% and specificity of 84% for predicting onset of HE within 2 years.
CONCLUSIONS: In patients with cirrhosis, ER 15 or CES 20 were equivalent or better predictors of major morbidity and mortality compared with commonly used clinical scores.
KEY POINTS: • Gadoxetate parameters may identify cirrhotic patients at risk of adverse events. • Gadoxetate parameters usually show superior predictive values compared to clinical scores. • CES 20 score is associated with risk of mortality within 2 years.
引用
- Sandrasegaran K, Cui E, Elkady R, et al. Can functional parameters from hepatobiliary phase of gadoxetate MRI predict clinical outcomes in patients with cirrhosis? Eur Radiol. 2018. PMID: 29651764. doi:10.1007/s00330-018-5366-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。